Ghatnekar Ola, Persson Ulf, Asplund Kjell, Glader Eva-Lotta
Department of Public Health and Clinical Medicine,Umeå University.
Swedish Institute for Health Economics.
Int J Technol Assess Health Care. 2014 Apr;30(2):203-9. doi: 10.1017/S0266462314000075.
The aim of this study was to estimate direct and indirect excess costs attributable to stroke in Sweden in 2009 and to compare these with similar estimates from 1997.
Data on first-ever stoke admissions in the first half of 2009 from the Swedish national stroke register (RS) were used for cost calculations and compared with results from 1997 also using RS data. A societal perspective was taken including the acute and follow-up phase, rehabilitation, stroke re-admissions, drugs, home- and residential care services for activities of daily life (ADL) support, and indirect costs for premature death and productivity losses (2009 prices). Survival was extrapolated to estimate the lifetime present value cost of stroke.
The societal lifetime present value cost for stroke in 2009 was €68,800 per patient (ADL support: 59 percent; productivity losses: 21 percent). Women had higher costs than men in all age groups as a result from greater need for ADL support. Patients treated at a stroke unit indicated low incremental cost per life-year gained compared with those who had not. The total lifetime cost increased between 1997 and 2009. Hospitalization costs per patient were stable, while long-term costs for home- and residential care services increased.
Changes in patient characteristics, longer expected survival, and possibly in the Swedish stroke care, have led to higher annual and lifetime costs per patient in 2009 compared with 1997. A comprehensive national stroke care performance register like RS may be suitable for health economic assessments.
本研究旨在估算2009年瑞典脑卒中所致的直接和间接额外成本,并将其与1997年的类似估算结果进行比较。
使用瑞典国家脑卒中登记册(RS)中2009年上半年首次脑卒中入院的数据进行成本计算,并与同样使用RS数据的1997年结果进行比较。研究采用社会视角,涵盖急性期和随访期、康复、脑卒中再次入院、药物、日常生活活动(ADL)支持的家庭和住院护理服务,以及过早死亡和生产力损失的间接成本(2009年价格)。通过外推生存率来估算脑卒中的终身现值成本。
2009年脑卒中的社会终身现值成本为每位患者68,800欧元(ADL支持:59%;生产力损失:21%)。由于对ADL支持的需求更大,各年龄组女性的成本均高于男性。在脑卒中单元接受治疗的患者与未接受治疗的患者相比,每获得一个生命年的增量成本较低。1997年至2009年期间,终身总成本有所增加。每位患者的住院成本保持稳定,而家庭和住院护理服务的长期成本有所增加。
与1997年相比,患者特征的变化、预期生存期延长以及瑞典脑卒中护理可能的变化,导致2009年每位患者的年度和终身成本更高。像RS这样全面的国家脑卒中护理绩效登记册可能适用于卫生经济评估。